Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (181-190 of 189) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 189 results.
Leukemia|June 6, 2017
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemiaS Tharkar-Promod, D P Johnson, S E Bennett, et al.
Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Nature Communications|May 11, 2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaFeng Wang, Kiyomi Morita, Courtney D DiNardo, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid MalignanciesCourtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Leukemia|August 23, 2024
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international communityBranko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, et al.
Pageof 19

Showing results (181-190 of 189) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 189 results.
Leukemia|June 6, 2017
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemiaS Tharkar-Promod, D P Johnson, S E Bennett, et al.
Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Nature Communications|May 11, 2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaFeng Wang, Kiyomi Morita, Courtney D DiNardo, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Patrick K Reville, Xuemei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid MalignanciesCourtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, et al.
Leukemia|August 23, 2024
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international communityBranko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, et al.
Pageof 19